Lentigen licenses Cambridge University technology

Licence agreement

Lentigen Corporation of Baltimore, Maryland, has agreed an exclusive licensing agreement with Cambridge Enterprise, the technology transfer arm of Cambridge University, for lentiviral gene technology developed Professor Andrew Lever.

The patent broadly claims fundamental compositions of HIV-based lentiviral vectors that are currently widely used in research and clinical studies. Boro Dropulic, president and chief scientific officer of Lentigen, said, “We are delighted to be working with Professor Lever in obtaining this patent license, and developing its application in biomedicine.”

Earlier this year Lentigen secured access to other lentiviral vector technology when GBP Capital, the company’s majority shareholder, acquired Cell Genesys, another biotech company working in the field.

“Licensing this fundamental technology patent from Cambridge extends our intellectual property position and is consistent with our goal of becoming a leader in lentiviral-vector based biomedicine,” said Tim Ravenscroft, chief executive officer of Lentigen.